Esmethadone Hydrochloride is a small molecule commercialized by Relmada Therapeutics, with a leading Phase II program in Treatment Resistant Depression. According to Globaldata, it is involved in 15 clinical trials, of which 11 were completed, 3 are ongoing, and 1 is planned. GlobalData uses proprietary data and analytics to provide a complete picture of Esmethadone Hydrochloride’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
Smarter leaders trust GlobalData
The revenue for Esmethadone Hydrochloride is expected to reach an annual total of $185 mn by 2035 globally based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
Esmethadone Hydrochloride Overview
REL-1017 (D-methadone) is under development for the treatment of major depressive disorder, treatment resistant depression, liver and renal failure. The drug candidate is administered through oral route as a solution and tablet. The drug candidate is a nonopioid analgesic which acts by targeting N-methyl-D-aspartate (NMDA) receptor. It is a d optical isomer of racemic methadone. It is a new chemical entity.
It was also under development for the treatment of post herpetic neuralgia, Rett syndrome, ophthalmology, mitochondrial diseases, amyotrophic lateral sclerosis, substance (drug) abuse and neuropathic pain and restless leg syndrome.
Relmada Therapeutics Overview
Relmada Therapeutics is a clinical-stage biotechnology company. It focuses on the development of esmethadone (d-methadone, dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist. The company’s pipeline product esmethadone is used for the treatment of central nervous system (CNS) diseases and other disorders. It conducts various phases of clinical trials like Phase I and II. The company also carries out research and development. Relmada Therapeutics is headquartered in Coral Gables, Florida, the US.
The operating loss of the company was US$103.7 million in FY2023, compared to an operating loss of US$161.3 million in FY2022. The net loss of the company was US$98.8 million in FY2023, compared to a net loss of US$157 million in FY2022.
For a complete picture of Esmethadone Hydrochloride’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, drug margins and company expenses. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.
The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate valuation, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA) and phase transition success rate (PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.
